Coyne Terrance P.

Coyne Terrance P., EVP & CFO of Royalty Pharma (NASDAQ: RPRX), has demonstrated a consistent pattern of selling activity over the past several months, with no recorded purchases in the same period. Since November 2025, Coyne has executed 24 sales of RPRX shares totaling over $31.4 million, with transactions occurring nearly every month. The sales have ranged from smaller dispositions—such as $23,686.73 and $120,882.11 on November 24, 2025—to significantly larger transactions, including a $4.66 million sale on February 3, 2026, and a $4.32 million sale the day prior. Notably, multiple sales often occur on the same day, suggesting structured dispositions, such as the pair of transactions on March 23, 2026, which amounted to $85,366.31 and $1.5 million, respectively. The absence of any buy transactions in Coyne’s recent filings indicates a clear divestment trend rather than accumulation. The regularity of sales—often clustered around month-end or early-month dates—could point to prearranged trading plans, though the filings do not specify this. The largest single-sale value within the dataset was the $4.66 million transaction in early February 2026, while the smallest was the $27,409.34 sale on March 2, 2026. Given that all transactions involve RPRX, Coyne’s activity remains concentrated in his executive role at Royalty Pharma, with no diversification into other securities evident in the filings. The sustained selling pattern suggests ongoing liquidation rather than sporadic rebalancing.